ReviewJACC. Asia2025
Cardiovascular Implications of Lipoprotein(a) and its Genetic Variants: A Critical Review From the Middle East.
Review in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Expert consensus on Lipoprotein(a) in the Gulf countries: Navigating cardiovascular risk and therapeutic advances.Atherosclerosis plus · 2026Article
- The Statin Floor Effect: a Mechanistic Framework for Residual Cardiovascular Risk.Cardiovascular drugs and therapy · 2026Review
- Recent advances in understanding the spectrum of genetic determinants of lipoprotein(a) levels.Current opinion in lipidology · 2026Review
- Ethnic Variation in Lipoprotein(a) Levels in the Kazakhstan Population.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dyslipidemia, a significant risk factor for cardiovascular diseases (CVDs), is prevalent in the Middle East (ME) countries. With a variable prevalence, elevated lipoprotein (a) [Lp(a)] is the most widespread monogenic dyslipidemic disorder. Genetic studies have established Lp(a) as a heritable and independent risk factor for CVD. This discovery has shifted the perception of Lp(a) and the LPA gene from mere biomarkers of atherosclerotic risk to a viable target for therapeutic intervention. Significant differences in serum Lp(a) levels have been observed across racial and ethnic groups, with few independent genetic variants affecting Lp(a) levels outside the LPA gene region. Data specific to the ME and Arab populations remains scarce. ME populations exhibit genetic diversity and higher consanguinity rates, which may uniquely influence Lp(a) distribution and associated variations. This review examines the genetic and observational factors that shape Lp(a) levels and their role in CVD risk, focusing on ME populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.